top of page

NEWS & INSIGHTS

Dive into the Biopharma Space

Stay up-to-date on major biopharma news, deeper dives into specific companies and biopharma themes, and how it all relates to biopharma partners.

Biopharma News - June 12th to June 16th 2023

Acquisitions, Alzheimer's data, collaborations, and more..

Are you a CRO, CMO, or Biopharma vendor? BiopharmIQ MarketCompass is a sales intelligence tool to help with your business development. Get a free sample report of potential targets.


CLINICAL TRIAL NEWS

Gracell Biotechnologies

Presented longer-term follow-up data from a first-in-human study evaluating GC012F, a CD19 and B-cell maturation antigen (BCMA) dual-targeted autologous CAR-T therapeutic candidate, in patients with relapsed/refractory B-cell non-Hodgkin’s Lymphoma (r/r B-NHL) as an oral presentation at EHA 2023.


Journey Medical Corporation

Announced positive topline data from their Phase 1 clinical trial assessing the impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on the microbial flora of healthy adults. DFD-29 is being developed for the treatment of papulopustular rosacea (“PPR”) in collaboration with Dr. Reddy’s Laboratories Ltd.


Acumen Pharmaceuticals

Announced that it will present topline results from their Phase 1 trial of ACU193, an AβO-directed antibody therapy, at the Alzheimer’s Association International Conference (AAIC) 2023 taking place from July 16-20, 2023.


REGULATORY NEWS

Mersana Therapeutics

Announced that the FDA has issued a partial clinical hold pausing new patient enrollment in UP-NEXT and UPGRADE-A, the company’s ongoing clinical trials of UpRi in platinum-sensitive ovarian cancer. Mersana’s recent assessment determined that serious bleeding events appear to occur at a higher rate than background.


M&A / COLLABORATION NEWS

Chinook Therapeutics

Announced that they have entered into an agreement and plan of merger with Novartis AG pursuant to which Novartis will acquire Chinook for $3.2 billion. Total consideration including the contingent value right, if the milestones are achieved, would be approximately $3.5 billion.


Agile Therapeutics

Announced an agreement with vitaCare Prescription Services, to expand patient access and streamline fulfillment for Twirla (levonorgestrel ethinyl estradiol) transdermal system. VitaCare is a technology and services platform that helps patients navigate key access barriers for branded medications. Company projects 2023 overall net revenue of $25-$30 million.


Verve Therapeutics

Announced an exclusive research collaboration with Eli Lilly focused on advancing Verve’s preclinical stage in vivo gene editing program targeting lipoprotein(a) (Lp(a)). Under the terms of the collaboration, Verve will advance the research and development of the Lp(a) program through the completion of Phase 1 clinical development. Lilly will be responsible for subsequent development, manufacturing, and commercialization of the Lp(a) program.


Coherus Biosciences

Announced they will acquire Surface Oncology, a clinical-stage immuno-oncology (I-O) company developing next-generation immunotherapies that target the tumor microenvironment. The acquisition adds two differentiated clinical stage assets to Coherus’ novel I-O pipeline: SRF388, a novel IL-27-targeted antibody currently being evaluated in Phase 2 clinical trials in lung cancer and liver cancer, and SFR114, a CCR8-targeted antibody currently in a Phase 1/2 study as a monotherapy in patients with advanced solid tumors.

 

Are you a CRO, CMO, or Biopharma vendor? BiopharmIQ MarketCompass is a sales intelligence tool to help with your business development. Get a free sample report of potential targets.

bottom of page